UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

The New England journal of medicine, 2020-04, Vol.382 (16), p.1497-1506

2020

Volltextzugriff (PDF)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

European archives of psychiatry and clinical neuroscience, 2023-10, Vol.273 (7), p.1543-1556

2023

Volltextzugriff (PDF)

Challenges in the clinical development of non-D2 compounds for schizophrenia

Current medical research and opinion, 2023-03, Vol.39 (3), p.467-471

2023

Volltextzugriff (PDF)

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D 2 Receptor Mechanism of Action

The Journal of pharmacology and experimental therapeutics, 2019-10, Vol.371 (1), p.1-14

2019

Volltextzugriff (PDF)

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans

Translational psychiatry, 2021-04, Vol.11 (1), p.228-228, Article 228

2021

Volltextzugriff (PDF)

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

Journal of affective disorders, 2022-01, Vol.296, p.549-558

2022

Volltextzugriff (PDF)

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

Molecular psychiatry, 2021-06, Vol.26 (6), p.2562-2576

2021

Volltextzugriff (PDF)

Review of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist Ulotaront: Part II—Summary of Initial Clinical Efficacy/Safety Results

CNS spectrums, 2023-04, Vol.28 (2), p.221-221

2023

Volltextzugriff (PDF)

Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)

Psychiatry research, 2020-12, Vol.294, p.113569-113569, Article 113569

2020

Volltextzugriff (PDF)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

Clinical drug investigation, 2021-12, Vol.41 (12), p.1067-1073

2021

Volltextzugriff (PDF)

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia

Schizophrenia bulletin, 2018-04, Vol.44 (3), p.593-602

2018

Volltextzugriff (PDF)

A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression

Contemporary clinical trials, 2024-10, Vol.145, p.107644, Article 107644

2024

Volltextzugriff (PDF)

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy

Sleep medicine, 2023-07, Vol.107, p.202-211

2023

Volltextzugriff (PDF)

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults

Neuropsychopharmacology (New York, N.Y.), 2015-11, Vol.40 (12), p.2745-2752

2015

Volltextzugriff (PDF)

Review of the TAAR1 Agonist Ulotaront: Part I—From Discovery to Clinic

CNS spectrums, 2023-04, Vol.28 (2), p.221-221

2023

Volltextzugriff (PDF)

TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner

Neuropsychopharmacology (New York, N.Y.), 2024-06, Vol.49 (7), p.1091-1103

2024

Volltextzugriff (PDF)

Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats

Drug and alcohol dependence, 2022-02, Vol.231, p.109261-109261, Article 109261

2022

Volltextzugriff (PDF)

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS

Clinical drug investigation, 2022-12, Vol.42 (12), p.1113-1121

2022

Volltextzugriff (PDF)

Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [18F]-DOPA Positron Emission Tomography Study

Biological psychiatry (1969), 2024-10, Vol.96 (8), p.674-683

2024

Volltextzugriff (PDF)

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

ACS medicinal chemistry letters, 2022-01, Vol.13 (1), p.92-98

2022

Volltextzugriff (PDF)

A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels

Advances in therapy, 2024, Vol.41 (1), p.152-169

2024

Volltextzugriff (PDF)

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

Clinical pharmacokinetics, 2023-12, Vol.62 (12), p.1755-1763

2023

Volltextzugriff (PDF)

Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial

International clinical psychopharmacology, 2021-05, Vol.36 (3), p.117-125

2021

Volltextzugriff (PDF)

Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting

Translational psychiatry, 2023-12, Vol.13 (1), p.388-388, Article 388

2023

Volltextzugriff (PDF)

Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial

Journal of child and adolescent psychopharmacology, 2019-03, Vol.29 (2), p.80-89

2019

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Aktive Filter

KollektionWiley-Blackwell Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

Challenges in the clinical development of non-D2 compounds for schizophrenia

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D 2 Receptor Mechanism of Action

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

Review of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist Ulotaront: Part II—Summary of Initial Clinical Efficacy/Safety Results

Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia

A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults

Review of the TAAR1 Agonist Ulotaront: Part I—From Discovery to Clinic

TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner

Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS

Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [18F]-DOPA Positron Emission Tomography Study

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial

Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting

Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial

Aktive Filter

Suchergebnisse filtern